On October 14, the Party Committee of the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council held an expanded meeting, clearly stating the need to strengthen the core functions of the healthcare industry and leverage the leading role of state-owned capital. The meeting required guidance and support for relevant central enterprises to strengthen pharmaceutical innovation, high-end medical equipment, and emergency supplies for public health, accelerate core technology breakthroughs and commercialization of research outcomes, and promote innovation in product offerings and service models in a coordinated manner, to help build a modern pharmaceutical and healthcare industry system. Meanwhile, the meeting emphasized resolving key challenges in central enterprises' operation of medical institutions, actively coordinating with local governments and health authorities, deeply integrating into the healthcare system, and consolidating the foundation for sustainable development of central enterprise medical institutions.
On October 13, the National Healthcare Security Administration convened a meeting, proposing active support for pharmaceutical technological innovation, with a focus on exploring the establishment of a "pre-establishment system for medical service pricing." This mechanism aims to shorten the access cycle for innovative drugs and medical devices from approval to clinical application, support faster clinical scaling of new pharmaceutical technologies and products, and remove bottlenecks in commercialization and volume expansion of innovative products through payment and access mechanisms.
Currently, the Hang Seng Index stands at 24,314, up 252 points or 1%, with main board turnover nearing HK$39.7 billion. The Hang Seng China Enterprises Index is at 8,184, up 80 points or 1%. The Hang Seng Tech Index is at 4,126, up 65 points or 1.6%.
| Stock (Code) | Current Price (HK$) | Change (%) |
|---|---|---|
| BeiGene (06160) | 227.4 | +5.47% |
| Innovent Biologics (01801) | 91.55 | +4.33% |
| China Biologic Products (01177) | 5.445 | +3.32% |
| WuXi Biologics (02269) | 50.5 | +3.82% |
| Hansoh Pharma (03692) | 32.42 | +3.31% |
| DualityBio-B (09606) | 172 | +12.2% |
| GenScript Biotech-1000 (01548) | 33.86 | +7.15% |
| Ascentage Pharma (06855) | 29.58 | +5.57% |
| Columbus Biosciences (06990) | 462 | +5.38% |
| Zai Lab (09688) | 18.7 | +4.18% |
| Akeso (09926) | 94.05 | +3.98% |
